DelveInsight’s, “Cirrhosis Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Cirrhosis pipeline landscape. It covers the Cirrhosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Cirrhosis Pipeline Report
- DelveInsight’s Cirrhosis pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Cirrhosis treatment.
- The leading companies working in the Cirrhosis Market include GWOXI Stem Cell Applied Technology, Lipocine, Galectin Therapeutics, Pharmicell Co., Ltd., BioVie, Ocera Therapeutics, Gilead Sciences, Chia Tai Tianqing Pharmaceutical Group, Zydus Cadila, Novartis Pharmaceuticals, Genfit, PRISM Pharma Co., Bristol-Myers Squibb, COUR Pharmaceutical Development Company, Inc., HighTide Biopharma, Gannex Pharma Co., Ltd., and others.
- Promising Cirrhosis Pipeline Therapies in the various stages of development include NGM282, Albutein 20% Injectable Solution, IDN-6556, GXHPC1, Caffeine Rosuvastatin, Digoxin, and others.
- On August 2023, Grifols Therapeutics LLC announced a study of Phase 3 Clinical Trials for Albutein 20% Injectable Solution. This is a phase 3, multicenter, randomized, controlled, parallel-group, and open-label clinical study to evaluate the efficacy of standard medical treatment (SMT) + Albutein 20% administration versus SMT alone in subjects with decompensated cirrhosis and ascites.
- On September 2023, AstraZeneca announced a study of Phase 2 Clinical Trials for zibotentan (dose B) + dapagliflozin. This is a two part Phase IIa/b multicentre, randomised, double-blind, placebo-controlled, parallel group dose-ranging study to assess the efficacy, safety, and tolerability of the combination of zibotentan and dapagliflozin, and dapagliflozin monotherapy versus placebo in participants with cirrhosis with features of portal hypertension.
Request a sample and discover the recent advances in Cirrhosis Treatment Drugs @ Cirrhosis Pipeline Report
The Cirrhosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Cirrhosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Cirrhosis clinical trial landscape.
Cirrhosis Overview
Cirrhosis is scarring (fibrosis) of the liver caused by long-term liver damage. The scar tissue prevents the liver working properly. Cirrhosis is sometimes called end-stage liver disease because it happens after other stages of damage from conditions that affect the liver, such as hepatitis.
Find out more about Cirrhosis Treatment Drugs @ Drugs for Cirrhosis Treatment
Cirrhosis Emerging Drugs Profile
- GXHPC 1: GWOXI Stem Cell Applied Technology
- LPCN 1148: Lipocine
- Belapectin: Galectin Therapeutics
Cirrhosis Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Cirrhosis. The Cirrhosis companies which have their Cirrhosis drug candidates in the most advanced stage, i.e. phase II/III include, Galectin Therapeutics.
Learn more about the emerging Cirrhosis Pipeline Therapies @ Cirrhosis Clinical Trials Assessment
Scope of the Cirrhosis Pipeline Report
- Coverage- Global
- Cirrhosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Cirrhosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Cirrhosis Companies- GWOXI Stem Cell Applied Technology, Lipocine, Galectin Therapeutics, Pharmicell Co., Ltd., BioVie, Ocera Therapeutics, Gilead Sciences, Chia Tai Tianqing Pharmaceutical Group, Zydus Cadila, Novartis Pharmaceuticals, Genfit, PRISM Pharma Co., Bristol-Myers Squibb, COUR Pharmaceutical Development Company, Inc., HighTide Biopharma, Gannex Pharma Co., Ltd., and others.
- Cirrhosis Pipeline Therapies- NGM282, Albutein 20% Injectable Solution, IDN-6556, GXHPC1, Caffeine Rosuvastatin, Digoxin, and others.
Dive deep into rich insights for new drugs for Cirrhosis Treatment, Visit @ Cirrhosis Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Cirrhosis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Cirrhosis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase II/III)
- Belapectin: Galectin Therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- GXHPC 1: GWOXI Stem Cell Applied Technology
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Cirrhosis Key Companies
- Cirrhosis Key Products
- Cirrhosis- Unmet Needs
- Cirrhosis- Market Drivers and Barriers
- Cirrhosis- Future Perspectives and Conclusion
- Cirrhosis Analyst Views
- Cirrhosis Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking